Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer

Annals of Surgery

Volumn 250, Issue 5, 2009, Pages 729-736

  Maher, Stephen G ^a   Gillham, Charles M ^b   Duggan, Shane P ^c   Smyth, Paul C ^a   Miller, Nicola ^a   Muldoon, Cian ^b   O'Byrne, Kenneth J ^b   Sheils, Orla M ^a   Hollywood, Donal ^b   Reynolds, John V ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c Departments of Clinical Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA HYBRIDIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; VALIDATION PROCESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TREATMENT OUTCOME;

EID: 70449440737     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181bce7e1     Document Type: Article

References (29)

1. Enzinger PC, Ilson DH. Irinotecan in esophageal cancer. Oncology (Williston Park). 2000;14(suppl 14):26-30.
2. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemora-diotherapy in oesophageal cancer. Br J Surg. 2001;88:338-356.
3. Chirieac LR, Swisher SG, Ajani JA, et al. Post-therapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preopera-tive chemoradiation. Cancer. 2005;103:1347-1355.
4. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009
5. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
6. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335:462-467.
7. Walshe L, Rowley S, Coffey M, et al. Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus. Dis Esophagus. 2007;20:217-224.
8. Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol. 2002;80:119-120.
9. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686.
10. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
11. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279-284.
12. Simon R. Challenges of microarray data and the evaluation of gene expression profile signatures. Cancer Invest. 2008;26:327-332.
13. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-2174.
14. Kihara C, Tsunoda T, Tanaka T, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 2001;61:6474-6479.
15. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259-267.
16. Zhou J, Wang H, Lu A, et al. A novel gene, NMES1, downregulated in human esophageal squamous cell carcinoma. Int J Cancer. 2002;101:311-316.
17. Arai M, Imazeki F, Sakai Y, et al. Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2'-deoxycytidine, in esophageal squamous cell carcinoma. Oncol Rep. 2008;20:405-412.
18. Reid T, Furuyashiki T, Ishizaki T, et al. Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem. 1996;271:13556-13560.
19. Liu CA, Wang MJ, Chi CW, et al. Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene. 2004;23:8731-8742.
20. Kleer CG, Zhang Y, Merajver SD. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs. 2007;185:95-99.
21. Lin CG, Leu SJ, Chen N, et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 2003;278:24200-24208.
22. Cooper RA, Wilks DP, Logue JP, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res. 1998;4:2795-2800.
23. Koukourakis MI, Giatromanolaki A, Fountzilas G, et al. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res. 2000;6:381-389.
24. Heller G, Geradts J, Ziegler B, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat. 2007;103:283-291.
25. Wong SY, Haack H, Kissil JL, et al. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA. 2007;104:12784-12789.
26. Haase D, Meister M, Muley T, et al. FRMD3, a novel putative tumor suppressor in NSCLC. Oncogene. 2007;26:4464-4468.
27. Liang QC, Xiong H, Zhao ZW, et al. Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Lett. 2009;273:164-171.
28. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA. 2008;105:18490-18495.
29. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362-369.